Activation of dopamine D2 receptors simultaneously ameliorates various metabolic features of obese women

American Journal of Physiology - Endocrinology and Metabolism

Volumn 291, Issue 5, 2006, Pages

  Kok, Petra ^a   Roelfsema, Ferdinand ^a   Frölich, Marijke ^a   Van Pelt, Johannes ^a   Stokkel, Marcel P M ^a   Meinders, A Edo ^a   Pijl, Hanno ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

d2r agonist; Food intake; Insulin resistance; Metabolic syndrome; Prolactin

Indexed keywords

BROMOCRIPTINE; DOPAMINE 2 RECEPTOR; FATTY ACID; GLUCOSE; INSULIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; CALORIC INTAKE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFECT; DYSLIPIDEMIA; ENERGY BALANCE; ENERGY EXPENDITURE; ENERGY METABOLISM; FATTY ACID BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPOGENESIS; LIPOLYSIS; MENSTRUAL CYCLE; METABOLIC DISORDER; METABOLIC SYNDROME X; NAUSEA; OBESITY; OXIDATION; OXYGEN CONSUMPTION; PATHOGENESIS; PRIORITY JOURNAL; SINGLE BLIND PROCEDURE; TRIACYLGLYCEROL BLOOD LEVEL; URINALYSIS; VOMITING;

ADULT; BLOOD GLUCOSE; BROMOCRIPTINE; CALORIMETRY, INDIRECT; CIRCADIAN RHYTHM; CROSS-OVER STUDIES; DOPAMINE AGONISTS; EATING; ENERGY METABOLISM; FATTY ACIDS, NONESTERIFIED; FEMALE; HUMANS; INSULIN; INSULIN RESISTANCE; METABOLIC SYNDROME X; MIDDLE AGED; NITROGEN; OBESITY; OXYGEN CONSUMPTION; PROLACTIN; RECEPTORS, DOPAMINE D2; UREA;

EID: 33751169810     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00567.2005     Document Type: Article

References (39)

1. Bina KG and Cincotta AH. Dopaminergic agonists normalize elevated hypothalamic neuropeptide Y and corticotropin-releasing hormone, body weight gain, and hyperglycemia in ob/ob mice. Neuroendocrinology 71: 68-78, 2000.
2. Blake GM and Fogelman I. Technical principles of dual energy x-ray absorptiometry. Semin Nucl Med 27: 210-228, 1997.
3. Bole-Feysot C, Goffin V, Edery M, Binart N, and Kelly PA. Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr Rev 19: 225-268, 1998.
4. Carey RM, Van Loon GR, Baines AD, and Kaiser DL. Suppression of basal and stimulated noradrenergic activities by the dopamine agonist bromocriptine in man. J Clin Endocrinol Metab 56: 595-602, 1983.
5. Cincotta AH, Luo S, Zhang Y, Liang Y, Bina KG, Jetton TL, and Scislowski PW. Chronic infusion of norepinephrine into the VMH of normal rats induces the obese glucose-intolerant state. Am J Physiol Regul Integr Comp Physiol 278: R435-R444, 2000.
6. Cincotta AH, MacEachern TA, and Meier AH. Bromocriptine redirects metabolism and prevents seasonal onset of obese hyperinsulinemic state in Syrian hamsters. Am J Physiol Endocrinol Metab 264: E285-E293, 1993.
7. Cincotta AH and Meier AH. Reductions of body fat stores and total plasma cholesterol and triglyceride concentrations in several species by bromocriptine treatment. Life Sci 45: 2247-2254, 1989.
8. Cincotta AH and Meier AH. Bromocriptine inhibits in vivo free fatty acid oxidation and hepatic glucose output in seasonally obese hamsters (Mesocricetus auratus). Metabolism 44: 1349-1355, 1995.
9. Cincotta AH and Meier AH. Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects. Diabetes Care 19: 667-670, 1996.
10. Cincotta AH, Schiller BC, and Meier AH. Bromocriptine inhibits the seasonally occurring obesity, hyperinsulinemia, insulin resistance, and impaired glucose tolerance in the Syrian hamster, Mesocricetus auratus. Metabolism 40: 639-644, 1991.
11. Cincotta AH, Tozzo E, and Scislowski PW. Bromocriptine/SKF38393 treatment ameliorates obesity and associated metabolic dysfunctions in obese (ob/ob) mice. Life Sci 61: 951-956, 1997.
12. Dhasmana KM, Villalon CM, Zhu YN, and Parmar SS. The role of dopamine (D2), alpha and beta-adrenoceptor receptors in the decrease in gastrointestinal transit induced by dopamine and dopamine-related drugs in the rat. Pharmacol Res 27: 335-347, 1993.
13. Di Chiara G, Porceddu ML, Vargiu L, and Gessa GL. Stimulation of "regulatory" dopamine receptors by bromocriptine (CB-154). Pharmacology 16, Suppl 1: 135-142, 1978.
14. Esler M, Rumantir M, Wiesner G, Kaye D, Hastings J, and Lambert G. Sympathetic nervous system and insulin resistance: from obesity to diabetes. Am J Hypertens 14: 304S-309S, 2001.
15. Kalra SP, Dube MG, Pu S, Xu B, Horvath TL, and Kalra PS. Interacting appetite-regulating pathways in the hypothalamic regulation of body weight. Endocr Rev 20: 68-100, 1999.
16. Kamath V, Jones CN, Yip JC, Varasteh BB, Cincotta AH, Reaven GM, and Chen YD. Effects of a quick-release form of bromocriptine (Ergoset) on fasting and postprandial plasma glucose, insulin, lipid, and lipoprotein concentrations in obese nondiabetic hyperinsulinemic women. Diabetes Care 20: 1697-1701, 1997.
17. Kotz CM, Briggs JE, Grace MK, Levine AS, and Billington CJ. Divergence of the feeding and thermogenic pathways influenced by NPY in the hypothalamic PVN of the rat. Am J Physiol Regul Integr Comp Physiol 275: R471-R477, 1998.
18. Kuo DY. Co-administration of dopamine D1 and D2 agonists additively decreases daily food intake, body weight and hypothalamic neuropeptide Y level in rats. J Biomed Sci 9: 126-132, 2002.
19. Leibowitz SF and Rossakis C. Pharmacological characterization of perifornical hypothalamic dopamine receptors mediating feeding inhibition in the rat. Brain Res 172: 115-130, 1979.
20. Liang Y, Lubkin M, Sheng H, Scislowski PW, and Cincotta AH. Dopamine agonist treatment ameliorates hyperglycemia, hyperlipidemia, and the elevated basal insulin release from islets of ob/ob mice. Biochim Biophys Acta 1405: 1-13, 1998.
21. Luo S, Liang Y, and Cincotta AH. Intracerebroventricular administration of bromocriptine ameliorates the insulin-resistant/glucose-intolerant state in hamsters. Neuroendocrinology 69: 160-166, 1999.
22. Luo S, Meier AH, and Cincotta AH. Bromocriptine reduces obesity, glucose intolerance and extracellular monoamine metabolite levels in the ventromedial hypothalamus of Syrian hamsters. Neuroendocrinology 68: 1-10, 1998.
23. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, and Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419, 1985.
24. Meier AH and Cincotta AH. Circadian rhythms regulate the expression of the thrifty genotype/phenotype. Diabetes Reviews 4: 464-487, 1996.
25. Meier AH, Cincotta AH, and Lovell WC. Timed bromocriptine administration reduces body fat stores in obese subjects and hyperglycemia in type II diabetics. Experientia 48: 248-253, 1992.
26. Missale C, Nash SR, Robinson SW, Jaber M, and Caron MG. Dopamine receptors: from structure to function. Physiol Rev 78: 189-225, 1998.
27. Osborn JW, Jacob F, and Guzman P. A neural set point for the long-term control of arterial pressure: beyond the arterial baroreceptor reflex. Am J Physiol Regul Integr Comp Physiol 288: R846-R855, 2005.
28. Parada MA, Hernandez L, and Hoebel BG. Sulpiride injections in the lateral hypothalamus induce feeding and drinking in rats. Pharmacol Biochem Behav 30: 917-923, 1988.
29. Pelletier G and Simard J. Dopaminergic regulation of pre-proNPY mRNA levels in the rat arcuate nucleus. Neurosci Lett 127: 96-98, 1991.
30. Pijl H. Reduced dopaminergic tone in hypothalamic neural circuits: expression of a "thrifty" genotype underlying the metabolic syndrome? Eur J Pharmacol 480: 125-131, 2003.
31. Pijl H, Ohashi S, Matsuda M, Miyazaki Y, Mahankali A, Kumar V, Pipek R, Iozzo P, Lancaster JL, Cincotta AH, and DeFronzo RA. Bromocriptine: a novel approach to the treatment of type 2 diabetes. Diabetes Care 23: 1154-1161, 2000.
32. Scislowski PW, Tozzo E, Zhang Y, Phaneuf S, Prevelige R, and Cincotta AH. Biochemical mechanisms responsible for the attenuation of diabetic and obese conditions in ob/ob mice treated with dopaminergic agonists. Int J Obes Relat Metab Disord 23: 425-431, 1999.
33. Sever PS. Alpha 1-blockers in hypertension. Curr Med Res Opin 15: 95-103, 1999.
34. Simonson DC and DeFronzo RA. Indirect calorimetry: methodological and interpretative problems. Am J Physiol Endocrinol Metab 258: E399-E412, 1990.
35. Stanley BG, Magdalin W, Seirafi A, Thomas WJ, and Leibowitz SF. The perifornical area: the major focus of (a) patchily distributed hypothalamic neuropeptide Y-sensitive feeding system(s). Brain Res 604: 304-317, 1993.
36. Tataranni PA, Baier L, Jenkinson C, Harper I, Del Parigi A, and Bogardus C. A Ser311Cys mutation in the human dopamine receptor D2 gene is associated with reduced energy expenditure. Diabetes 50: 901-904, 2001.
37. van den Hoek AM, Voshol PJ, Karnekamp BN, Buijs RM, Romijn JA, Havekes LM, and Pijl H. Intracerebroventricular neuropeptide Y infusion precludes inhibition of glucose and VLDL production by insulin. Diabetes 53: 2529-2534, 2004.
38. Wang GJ, Volkow ND, Logan J, Pappas NR, Wong CT, Zhu W, Netusil N, and Fowler JS. Brain dopamine and obesity. Lancet 357: 354-357, 2001.
39. Yang ZJ, Meguid MM, Chai JK, Chen C, and Oler A. Bilateral hypothalamic dopamine infusion in male Zucker rat suppresses feeding due to reduced meal size. Pharmacol Biochem Behav 58: 631-635, 1997.